Background. Left ventricular assist devices (LVAD)-associated infections are associated with fivefold higher 1-year mortality. Published literature is insufficient to inform clinicians regarding optimal management of bloodstream infection (BSI) in patients LVAD recipients. In particular, it is unclear which episodes of BSI may result in occult hematogenous seeding of the device surfaces, and therefore should be managed with chronic suppressive therapy (CAS). We aim to describe BSI, CAS, and breakthrough BSI in our LVAD population.
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Methods. We retrospectively reviewed 332 episodes of all LVAD infections at Mayo Clinic from 2007 to 2015. We categorized BSI as LVAD related/associated and LVAD nonrelated as defined by established criteria in the cardiac device literature. Our primary outcome was to describe breakthrough BSI in LVAD related and nonrelated infections in patients receiving CAS and those who were not.
Results. We identified 68 episodes of bacteremia in our LVAD population. Of these, 55 were proven BSI (see Fig 1) . In our study cohort, 45/55 (82%) were male and median patient age was 62 years. A majority of LVAD implants were destination therapy 34/55 (62%) and 35/55(64%) had a central line in place at the time of BSI. Twenty patients had non-VAD-related BSI and nine of these (9/20, 45%) patients were placed on CAS with two of these (2/9, 22%) had subsequent breakthrough BSI, whereas 11/20 (55%) were not placed on CAS with no breakthrough infections seen (Figure 1 ).
Conclusion. Our preliminary data suggest that routine use of CAS for non-VAD-related BSI is not necessary as only a minority go on to have breakthrough BSI. Limiting unnecessary use of antibiotics will have significant implications for stewardship and preventing emergence of resistance. Background. Multidrug-resistant Gram-negative bacterial infections have emerged as a significant cause of morbidity among solid-organ transplant (SOT) recipients, leading to challenges in selection of empiric antibiotic therapy. As such, we developed a predictive tool to determine whether these patients are high or low risk for extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (EB) bacteremia at the time of positive blood culture.
Methods. All SOT recipients admitted to the Hospital of the University of Pennsylvania with blood cultures positive for EB between January 2007 and July 2016 were included in the source cohort. Multivariate logistic regression was used to determine predictors of ESBL-EB bacteremia. Manual forward selection was utilized to maximize area under the receiver operating characteristic curve (AUC), with sequential addition of covariates until achieving an AUC increase of <1%. A scoring system was developed based on the adjusted odds ratios for each covariate. Interval validity was assessed using the Hosmer-Lemeshow statistic, sensitivity, specificity, and the bootstrapping technique.
Results. Over the study period, there were 287 SOT recipients admitted with an EB bacteremia, of which 51 were due to an ESBL-producing organism. The final model that predicted presentation with ESBL-EB bacteremia included: identification of an ESBL-EB on culture in the previous 12 months, trimethoprim-sulfamethoxazole exposure in the prior 6 months, receipt of a kidney transplant, and fluoroquinolone exposure in the prior 6 months. This model achieved an AUC of 0.85, sensitivity of 54.9%, specificity of 96.6%, and Hosmer-Lemeshow statistic of 0.26 (Figure 1) . Based on the adjusted odds ratios for each factor, scores of +3, +1, −1, and +1 were assigned to each covariate, respectively. With this scoring system, the maximum attainable score was 5, with any score of ≥3 deemed to be predictive of ESBL-EB bacteremia. After bootstrapping, the adjusted AUC remained at 0.85.
Conclusion. The presence of ESBL-EB organism as the etiology of bacteremia in SOT recipients can be predicted using the above scoring system. This tool will inform judicious empiric antibiotic use in this population at the time of positive blood culture.
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